Lymphoma Clinical Trials

Showing 2861-2880 of 3,379 trials

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

NCT00655837

The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma. This study is also intended to estimate how well your disease responds to this treatment.

Lymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Seagen Inc.33 participantsStarted Apr 2008

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Aurora, Colorado, United States +6 more locations

COMPLETEDPhase 1

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

NCT00103779

This is an open-label, multi-dose, Phase I, dose escalation study to define the safety profile and preliminary anti-tumor activity of SGN-40 in patients with refractory or recurrent non-Hodgkin B-cell lymphomas.

Non-Hodgkin Lymphoma

Seagen Inc.50 participantsStarted Dec 2004

Birmingham, Alabama, United States • Stanford, California, United States • Miami, Florida, United States +2 more locations

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Related Searches

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma

A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)